Aurinia Pharmaceuticals AUPH Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Kiniksa Pharmaceuticals International, plcKNSA

——

Alumis Inc.ALMS

——

BridgeBio PharmaBBIO

——

Ionis PharmaceuticalsIONS

——

Other financials

Income statement

See full

Revenue$77.7M+24.4%

Gross profit$71.2M+32.1%

Operating income$41.4M+89.6%

Net income$34.4M+47.2%

EPS (diluted)$0.25+56.3%

Balance sheet

See full

Cash & equivalents$41.0M-38.3%

Total debt$85.2M-7.9%

Total equity$567.6M+62.1%

Total assets$724.0M+43.4%

Cash flow

See full

Operating cash flow$32.6M+2,405%

Valuation

See full

Market cap$2.39B+78.5%

Enterprise value$2.44B+78.3%

P/E8×-25.6×

P/S8×+2.6×

Profitability

See full

Gross margin89.7%+1.5pp

Operating margin41.7%+29.4pp

Net margin100%+83.9pp

Returns & leverage

See full

Return on equity65%+53.8pp

Debt / equity0.2×-0.1×

Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Aurinia Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aurinia Pharmaceuticals's deferred revenue, net of current portion?: Aurinia Pharmaceuticals (AUPH) reported deferred revenue, net of current portion of $12.65M in Q4 2025.